



A Statement from Biogen on Access to LEQEMBI™

March 13, 2023

Biogen welcomes the U.S. Veterans Health Administration's (VHA) recent decision to provide coverage of LEQEMBI™ for veterans living with early stages of Alzheimer's disease. Additional details can be found in Eisai's [news release](#) announcing the coverage decision.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.